Neuro SysMed study awarded “Investigator Initiated Study of the Year”
The OVERLORD MS study, led by the MS research group at Neuro SysMed, Haukeland University Hospital and the University of Bergen, has been awarded “Investigator Initiated Study of the Year” at the national Award for Outstanding Contribution to Clinical Studies 2025. The prize was presented at the Grand Hotel in Oslo on 29 January, 2026.
Photo: Neuro-SysMed
The award is part of a new national prize scheme established by NorTrials, LMI, Melanor, Inven2, NorCRIN, and CONNECT. Its purpose is to highlight individuals and research environments that, through scientific excellence and commitment, contribute to high-quality clinical studies in Norway. The jury received around 100 nominations across six categories.
A study of great importance for both patients and the healthcare system
OVERLORD‑MS compares the effectiveness of two MS treatments: the more affordable off-label medicine rituximab, and the established but costly ocrelizumab. The study was conducted as a randomised, double-blinded, non‑inferiority trial with more than 200 participants across 12 hospitals in Norway and Sweden.
The results show that rituximab can provide treatment outcomes equivalent to ocrelizumab in patients with newly diagnosed relapsing‑remitting MS. The jury highlights that the study successfully combines patient benefit with societal benefit — improving treatment options while also offering significant cost savings for the healthcare system. The project is also recognised for its solid methodological quality and efficient execution.
International attention
OVERLORD‑MS has attracted significant international attention and is further reinforcing Norway’s standing as a leading contributor to MS research. At a time when many countries are seeking cost-effective and sustainable solutions, the study demonstrates how investigator-initiated projects can provide knowledge that quickly influences both clinical practice and health policy. Rituximab has now already been incorporated into the national guidelines for first-line treatment of MS.
We congratulate the research team on this recognition that reflects the strong and long-term efforts invested over many years!